Budget Pact, Not Compulsory Licensing Is Solution To Pricing Woes, Says Dutch Pharma
Executive Summary
The Dutch Pharmaceutical industry association is calling for an agreement with the government to control the medicines budget and wants to start a new conversation about drug pricing.
You may also be interested in...
Compulsory Licensing And Compounded Orkambi: Solutions For Excessive Prices In The Netherlands?
Compulsory licensing, new R&D models, and pharmaceutical compounding are among measures that could help secure lower drugs prices, according to a report from the Dutch Council for Public Health and Society.
Are Outcomes-Based Managed Entry Agreements Dead In Europe?
Outcomes-based managed entry agreements designed to help ensure access to expensive new medicines are not sustainable and have so far failed to provide a solution to the problem of funding costly innovative drugs, according to Ad Schuurman from ZIN, the Dutch National Healthcare Institute.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.